Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116686 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Sarah Blocker und 21 weiteren Autor:innen. Beteiligte Einrichtung: The University of Kansas Cancer Center, 2650 Shawnee Mission Pkwy, Westwood, KS 66205, USA. Hauptthemen laut MEDLINE: Cytokine Release Syndrome, Lung Neoplasms, Neurotoxicity Syndromes, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Tarlatamab is the preferred second-line therapy for extensive stage small cell lung cancer (ES-SCLC). However, strict eligibility criteria from trials limit the understanding of safety and efficacy in broader patient populations. METHODS: Patients with ES-SCLC treated with tarlatamab after platinum-based chemotherapy at nine cancer centers were included. Predefined univariate subgroup analyses for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) included age, performance status, disease burden (>3 metastatic tissue types involved), CNS disease, hepatic disease, and oxygen use among others. Efficacy endpoints were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: A total of 109 patients were analyzed across several high-risk features. Any grade CRS was significantly associated with high disease burden (p = 0.002), hepatic disease (p = 0.002), and baseline oxygen use (p = 0.034). Any grade ICANS was significantly associated with high disease burden (p = 0.022) and a history of treated or untreated CNS disease (p = 0.015). Within the subgroup of patients with CNS disease unstable brain metastasis was associated with higher any grade ICANS (p = 0.021). The ORR was 33.7%, PFS of 3.58 months, and median OS of 8.48 months. CNS-specific ORR was 33.3%, including four complete responses without radiation. CONCLUSION: High disease burden, hepatic disease, and baseline oxygen use may increase CRS risk with high disease burden and CNS disease driving ICANS risk. Tarlatamab demonstrated manageable toxicity with clinically relevant efficacy across high-risk patient populations supporting broad access to this therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Kansas Cancer Center, 2650 Shawnee Mission Pkwy, Westwood, KS 66205, USA.
- Huntsman Cancer Institute, 1950 Cir of Hope Dr, Salt Lake City, UT 84112, USA.
- Vanderbilt University Medical Center, 2220 Pierce Ave Suite 1710, Nashville, TN 37232, USA.
- Nebraska Medicine, 989200 Nebraska Medical Center, Omaha, NE 68198-9200, USA.
- Saint Luke's Hospital of Kansas City, 4401 Wornall road, Kansas City, MO 64111, USA.
- University of Michigan Health, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA.
Zitieren
APA
Blocker, S., Kim, D., Cavalieri, C. C., Cannon, S., Cass, A., Olinger, A., Bortka, B., Gustafson, B., Schepers, A., Hobbs, J., Blackwell, L., Holman, K., Li, H., Huang, C., Maksoud, J., Moore, T., Neupane, P., Zhang, J., Mullangi, S., …, & Schieber, T. (2026). Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116686
Vancouver
Blocker S, Kim D, Cavalieri CC, Cannon S, Cass A, Olinger A, et al. Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116686
BibTeX
@article{Blocker2026,
author = {Blocker, Sarah and Kim, Diana and Cavalieri, Courtney C and Cannon, Sabrina and Cass, Amanda and Olinger, Alexander and Bortka, Bryce and Gustafson, Beth and Schepers, Allison and Hobbs, Jacob and Blackwell, Lauren and Holman, Kori and Li, Haoran and Huang, Chao and Maksoud, Joey and Moore, Ty and Neupane, Prakash and Zhang, Jun and Mullangi, Sanjana and Grauer, Dennis and Lekkala, Manidhar Reddy and Schieber, Timothy},
title = {Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116686}
}
EUVIMED